AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment ...
PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10th 2022, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today …